Chargement

Slzii.com Recherche

Recherche (Nouvelles)

Cartesian Therapeutics: A Phase 3 mRNA CAR-T Bet

Cartesian Therapeutics: A Phase 3 mRNA CAR-T Bet
business

Cartesian Therapeutics' lead asset, Descartes-08, demonstrated a 7.1-point MG-ADL reduction at 12 months in Phase 2b. Find out why RNAC stock is a buy.
2026-04-23 08:19:30

Que fais-tu?
0.071783065795898


Nouvelles
Nouvelles

Dernières nouvelles et titres
Cartesian Therapeutics' lead asset, Descartes-08, demonstrated a 7.1-point MG-ADL reduction at 12 months in Phase 2b. Find out why RNAC stoc...
Nouvelles